Castle Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Castle Biosciences (CSTL) will present at Baird’s 2022 Global Healthcare Conference on Sept. 13, 2022, at 2:00 p.m. ET. The presentation, led by CEO Derek Maetzold and CFO Frank Stokes, will be available via a live audio webcast on their website, with a replay for 90 days. Additionally, they will participate in one-on-one investor meetings at the Lake Street Best Ideas Growth Conference on Sept. 14, 2022. Castle is focused on diagnostics for conditions like skin cancers and Barrett’s esophagus.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available on Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for 90 days following the conclusion of the live broadcast.

Castle will also be available for one-on-one investor meetings during the 6th Annual Lake Street Best Ideas Growth (BIG6) Conference on Sept. 14, 2022. Meetings may be requested exclusively through Lake Street Capital Markets.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005116/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When is Castle Biosciences' presentation at Baird’s 2022 Global Healthcare Conference?

Castle Biosciences will present on Sept. 13, 2022, at 2:00 p.m. Eastern time.

Who will represent Castle Biosciences at the Baird’s 2022 Global Healthcare Conference?

CEO Derek Maetzold and CFO Frank Stokes will represent Castle Biosciences.

How can I watch the Castle Biosciences conference presentation?

The presentation will be available via a live audio webcast on Castle Biosciences’ website.

Is there a replay available for the Castle Biosciences presentation?

Yes, a replay will be available for 90 days after the live presentation.

What other conference will Castle Biosciences attend after Baird’s Conference?

Castle Biosciences will participate in the Lake Street Best Ideas Growth Conference on Sept. 14, 2022.

What type of tests does Castle Biosciences offer?

Castle Biosciences offers tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions.